放开政府定价后我国药品价格调整方向与国际经验借鉴  

Discussing the pharmaceutical pricing strategy after canceling the government pricing in China

作　　者：陈文静[1] 汤少梁[1] 臧运森 田侃[1] 

机构地区：[1]南京中医药大学,江苏南京210023 [2]江苏省人民医院

出　　处：《中国卫生事业管理》2017年第1期29-32,共4页Chinese Health Service Management

基　　金：教育部2015年人文社会科学研究规划项目"基于HRQOL的国家基本药物制度福利效应提升研究"(编号:15YJA630060);江苏省2015年社会科学基金项目"取消药品政府定价政策背景下江苏省药品福利效应的动态演化与提升机制研究"(编号:15GLB014)

摘　　要：药品是保障民众健康的关键因素,除了安全性和有效性之外,影响其发挥作用的还有药品可及性,价格则是影响药品可及性的重要因素。在"新经济"阶段的要求下,市场决定资源配置,把握市场环境、合理的药品定价对保障有效药品可持续的供应具有重要意义。文章就当前我国药品定价放开之后,药品市场存在的一些问题,借鉴国外市场经济国家药品定价经验,提出适合我国药品市场的药品定价策略,为推动新医改药品定价思路提供有益的借鉴。Medicine is a critical factor to guarantee the people＇ s health, which needs to be ensured not only by the safety and effectiveness, but also the accessibility. The price of pharmaceuticals is an important factor to influence the accessibility. In the period of ＂New economy＂ in China, resource allocation was decided by the market, which means it is significant to grasp the market environment and pricing for the sustainable supply of effective medicines. The problems of pharmaceutical pricing strategy after canceling the government pricing in China were discussed. And some experiences of pharmaceutical pricing in other market e- conomy countries were studied. Based on which, some countermeasures were put forward to promote pharmaceutical pricing under the healthcare reform.

关 键 词：药品价格 医疗保险 定价策略 

分 类 号：R95[医药卫生—药学]